Targeted Protein Degradation (TPD)
mRNA-encoded protein degraders for selective elimination of disease-associated proteins
We develop targeted protein degradation strategies that harness cellular protein-degradation machinery to selectively eliminate disease-associated proteins. By integrating programmable degraders with mRNA delivery technologies, we aim to achieve precise and efficient regulation of intracellular therapeutic targets.
p53-Based Therapeutics
Restoring tumor-suppressor activity through engineered p53 therapeutics
We develop therapeutic strategies to restore and modulate the tumor-suppressive functions of p53 in cancer cells. By integrating protein engineering with advanced delivery technologies, we aim to reactivate p53-dependent anti-tumor responses and improve therapeutic efficacy.
T-Cell Engagers (TCE)
Engineered multispecific molecules for targeted T-cell recruitment and tumor killing
We develop T-cell engager molecules that redirect cytotoxic T cells toward tumor-associated targets. By engineering bispecific and multispecific engager formats, we aim to enhance tumor recognition, immune-cell recruitment, and selective anti-tumor activity.
CAR T-Cell Therapy
Engineering patient T cells for selective recognition and elimination of cancer cells
We develop CAR T-cell therapeutic strategies by genetically engineering T cells to recognize tumor-associated antigens and selectively eliminate cancer cells. By optimizing CAR design, target specificity, and T-cell activation, we aim to enhance anti-tumor efficacy while improving the precision and durability of cellular immunotherapy.
In Vivo Monocyte Engineering
Harnessing inflammation-guided monocyte trafficking for targeted brain therapeutics
We investigate strategies to engineer circulating monocytes directly in vivo and exploit their natural ability to migrate toward inflammatory and disease-associated lesions. By combining targeted delivery with disease-responsive gene expression, we aim to enable selective therapeutic protein production at brain disease sites while minimizing unwanted expression in healthy tissues.